MDT

96.07

-0.39%↓

146.68

-0.14%↓

VEEV

225

-2.38%↓

HQY

84.48

+1.71%↑

PHR.US

16.26

-1.16%↓

MDT

96.07

-0.39%↓

146.68

-0.14%↓

VEEV

225

-2.38%↓

HQY

84.48

+1.71%↑

PHR.US

16.26

-1.16%↓

MDT

96.07

-0.39%↓

146.68

-0.14%↓

VEEV

225

-2.38%↓

HQY

84.48

+1.71%↑

PHR.US

16.26

-1.16%↓

MDT

96.07

-0.39%↓

146.68

-0.14%↓

VEEV

225

-2.38%↓

HQY

84.48

+1.71%↑

PHR.US

16.26

-1.16%↓

MDT

96.07

-0.39%↓

146.68

-0.14%↓

VEEV

225

-2.38%↓

HQY

84.48

+1.71%↑

PHR.US

16.26

-1.16%↓

Home・Akcijų sąrašas・Akebia Therapeutics Inc

Akebia Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

1.36 -4.23

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.3599999999999999

Max

1.3599999999999999

Pagrindiniai rodikliai
By Trading Economics
Pajamos	293K 540K
Pardavimai	-3.7M 59M
Pelno marža	0.919
Darbuotojai	181
EBITDA	-1.2M 6.2M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+280.54% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-161M 401M
Ankstesnė atidarymo kaina	5.59
Ankstesnė uždarymo kaina	1.36

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

2.345 / N/A Palaikymas ir pasipriešinimas

Akebia Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-13 19:05; UTC

Pagrindinės rinkos jėgos

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

2026-01-13 23:41; UTC

Rinkos pokalbiai

Nikkei May Rise on Japan Election Hopes -- Market Talk

2026-01-13 23:41; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-13 23:33; UTC

Rinkos pokalbiai

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

2026-01-13 23:13; UTC

Įsigijimai, susijungimai, perėmimai

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

2026-01-13 23:10; UTC

Įsigijimai, susijungimai, perėmimai

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

2026-01-13 23:03; UTC

Rinkos pokalbiai

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

2026-01-13 21:50; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

2026-01-13 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-01-13 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

2026-01-13 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

2026-01-13 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

2026-01-13 21:15; UTC

Įsigijimai, susijungimai, perėmimai

VERSANT Completes Acquisition Of Free TV Networks >VSNT

2026-01-13 21:08; UTC

Įsigijimai, susijungimai, perėmimai

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

2026-01-13 20:39; UTC

Rinkos pokalbiai

Silver Settles at Another New High -- Market Talk

2026-01-13 20:21; UTC

Rinkos pokalbiai

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

2026-01-13 20:17; UTC

Rinkos pokalbiai

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

2026-01-13 19:08; UTC

Įsigijimai, susijungimai, perėmimai

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

2026-01-13 19:03; UTC

Uždarbis

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

2026-01-13 18:50; UTC

Uždarbis

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

2026-01-13 17:54; UTC

Rinkos pokalbiai

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

2026-01-13 17:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Global Equities Roundup: Market Talk

2026-01-13 17:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

2026-01-13 17:49; UTC

Rinkos pokalbiai

Analysts Call For Potential Record Ethanol Output -- Market Talk

2026-01-13 17:38; UTC

Rinkos pokalbiai

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

2026-01-13 17:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-13 17:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-13 17:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-01-13 17:19; UTC

Rinkos pokalbiai

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

2026-01-13 17:15; UTC

Rinkos pokalbiai

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Akcijų palyginimas

Kainos pokytis

Akebia Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

280.54% į viršų

12 mėnesių prognozė

Vidutinis 5.67 USD 280.54%

Aukščiausias 6 USD

Žemiausias 5 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Akebia Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių Akebia Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

2.345 / N/APalaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bullish.

Finansinės naujienos

Apie bendrovę Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.